Heparin, a polyanionic glycosaminoglycan, is used routinely prior to the induction of cardiopulmonary bypass. Earlier observations in our laboratory suggested that the postoperative bleeding which occurs, despite neutralization of heparin with prdtamine, is secondary to hypothermia and dilutional anemia during bypass. An additional, potential mechanism for excessive bleeding following cardiopulmonary bypass is that heparin activates the fibrinolytic system, which may, in turn, adversely affect hemostasis. To understand better the effects of heparin administration on the fibrinolytic system in vivo, we simulated the anticoagulant regimen of cardiopulmonary bypass by administering increasing doses of intravenous heparin to five adult baboons over 60 minutes. We measured fibrinolytic parameters serially following heparinization, and demonstrated that heparin induces activation of the fibrinolytic system. We showed that the fibrinolytic system was activated in vivo as evidenced by an increase in plasmin activity and immunoreactive plasmin light chain, as well as an increase in immunoreactive fibrinogen fragment E in yjtro. These results demonstrate that the fibrinolytic system is activated in vivo by the administration of heparin during cardiopulmonary bypass. These data suggest that, despite administration of a neutralizing agent such as protamine, heparin may contribute to postoperative bleeding complications following cardiopulmonary bypass surgery owing principally to its longer-lived effects on the fibrinolytic system.
Introduction
The generalized hemorrhagic tendency accompanying cardiopulmonary bypass has been recognized for over a decade. An abnormality in platelet function is believed to be the principal hemostatic defect underlying this hemorrhagic^tendency (16, 42, 17, 7) ; however, abnormalities in the coagulation and fibrinolytic systems have also been reported (26, 22) . We have recently attempted to characterize the specific defect in platelet function that accompanies cardiopulmonary bypass, and concluded that the defect is extrinsic to the platelet (21); intrinsic platelet function appears to be preserved.
The high circulating concentrations of heparin used during cardiopulmonary bypass are likely to account in part for platelet dysfunction.
Inactivation of circulating thrombin, the most important platelet agonist in vivo (15, 8, 20) , by antithrombin III is dependent upon heparin. In addition, the relative protection of thrombin from antithrombin III afforded by fibrin binding is overcome by the high concentrations of heparin used during cardiopulmonary bypass (40) [4.5 U/ml with an activated clotting time > 999 seconds in our original study (21)]. Coupled with the direct inhibitory effects of hypothermia on platelet activation (21, 36, 28) , the inhibition of thrombin by heparin provides a rational mechanism for attenuated platelet responses during bypass.
Heparin, however, has a number of profibrinolytic effects that have been appreciated for many years which could also contribute to platelet dysfunction (14, 10, 35, 9) .
Mechanisms by which this polydispersed glycosaminoglycan is believed to facilitate fibrinolysis are several and include direct stimulation of the release of plasminogen activator(s) from vascular (27) and monocytic cells; facilitation of the activation of protein C, promoting the release of plasminogen activator; impairment of fibrin monomer polymerization; enhancement of the catalytic efficiency of plasminogen activation by urokinase-type plasminogen activators and tissue-type plasminogen activator enhancement of plasmin-mediated activation of singlechain urokinase-type plasminogen activator; modulation of antiplasmin activities (12,2); catalysis of thrombin-induced neutralization of plasminogen activator inhibitor type 1; and potentiation of the effects of tissue factor pathway inhibitor, thereby reducing the modulatory prothrombotic effects that often accompany fibrinolysis. These in vitro observations, coupled with the recent reports on the in vivo benefits of aprotinin on blood loss during .
• cardiopulmonary bypass (39,37), suggest that heparin use may underlie the platelet dysfunction of cardiopulmonary bypass both by impairing thrombin activity and promoting the development of a fibrinolytic milieu in which platelet are rendered additionally dysfunctional.
In this report, we show simulated the anticoagulant regimen of cardiopulmonary bypass in normal baboons to show that these doses (10, 100, 400, and 500 U/kg) that heparin leads to plasminogen activation in vivo;
that the generation of plasmin is accompanied by evidence for its systemic lytic effects; and that platelets exposed to heparin in vivo are more susceptible to activation as determined by whole blood flow cytometry. The enhancement of the activation of plasminogen by heparin and the subsequent generation of plasmin likely contributes to the hemostatic defect of cardiopulmonary bypass.
Materials and Methods

Animal Protocol
This study was conducted on five male baboons, aged 15-25 years, at the Naval Blood Research Laboratory, Boston University School of Medicine, Boston, MA. Animal studies were performed in accordance with institutional Animal Care Committee regulations. Table 1 reports the hematologic and coagulation parameters in five baboons weighing 27.6 ± 1.0 kg prior to and following heparin administration. The design of this study was based on a progressive weight-adjusted increase in intravenous heparin administration.
Heparin was given after baseline laboratory studies were obtained at t = 0, and increasing doses were administered at 10, 20, 40 and 60 min (heparin doses = 10, 100, 400, and 500 U/kg, respectively). Ten minutes after each of the heparin doses was administered, blood samples were collected. Heparin (Abbott Laboratories, Abbott Park, IL) was neutralized at the end of the study period with protamine sulfate (Abbott Laboratories, Abbott Park, IL) (mean 118.8 +_ 37.5 mg, range 75-150 mg), and the efficacy of reversal was monitored by the measurement of the activated clotting time.
Blood Specimens: Acquisition and Assays
Blood was collected into tripotassium ethylenediaminetetraacetic acid (EDTA) for the measurement of hematocrit and platelet count using a Coulter JT counter (Coulter Electronics, Hialeah, FL). Whole blood was collected into trisodium citrate and centrifuged at 1000 x g for 10 min, and plasma samples were stored at -70°C until all samples could be assayed simultaneously. 
Samples
Western Blot Assays
The conversion of plasminogen to plasmin by activation of the fibrinolytic system was determined using Western blotting techniques. Plasma anticoagulated with 3.8% trisodium citrate was electrophoresed on a 7-1 5% gradient polyacrylamide gel under reducing conditions. The gel was transferred onto a polyvinylidene difluoride (PVDF) membrane and the membrane incubated with a göat polyclonal antihuman plasminogen antibody that cross-reacted with baboon plasminogen. Plasminogen was identified by its mobility and quantified by densitometry (30).
The in vivo activity of plasmin was determined by measuring selected fibrinogen degradation products using Western blotting techniques, as well.
Plasma anticoagulated with 3.8% trisodium citrate was electrophoresed on a 7-15% gradient polyacrylamide gel under nonreducing conditions. The gel was transferred onto a PVDF membrane and the membrane was incubated with a goat polyclonal antihuman fibrinogen antibody that cross-reacted with baboon fibrinogen. Fragment E was identified by its mobility and quantified by densitometry (30). 
Murine Monoclonal Antibodies
Measurement of Platelet Surface Clycoproteins
A whole blood flow cytometric method was used, as previously 
Data Analysis
Comparisons were made between data obtained before and after the administration of heparin using a paired Student's t-test. Values presented represent the mean ± S.E.M., and p values less than 0.05 were considered statistically significant.
Results
Calculated Heparin Dose and Serum Heparin Level
Heparin was administered to stimulate levels achieved during corresponding bypass as described in Materials and Methods based on the body weight of the animals in kilograms. At 10, 20, 40, and 60 mins, heparin was administered intravenously and cumulatively at 10, 100, 400, and 500 U/kg body weight. Ten minutes following heparin administration (20, 30, 50, and 70 min), blood was drawn for determination of heparin concentrations.
Actual plasma heparin concentrations were found to be 0.20 +. 0.01 U/ml, 1.32 +.0.07 U/ml, 7.80^0.13 U/ml, and 13.00 _+ 1.10 U/ml compared to a baseline plasma heparin level of <0.20 U/ml (p<0.001 compared to 30, 50, and 70 mins). Having demonstrated a linear correlation between plasmin activity and'
Effect of Heparin on Fibrinolysis
plasmin light chain generation, we next examined the effects of increasing heparin concentrations added /" vitro on plasmin light chain in baboon Plasma. Heparin, from 0.1 to 10 U/ml, was added to plasma, and plasmin light chain was quantified. Plasmin light chain increased following incubation of plasma with heparin at concentrations of 1 U/ml to" 10 U/ml. 
Effect of Heparin on Platelet Activation
Using flow cytometry of platelets obtained from baboons treated with heparin, we observed significant changes in P-selectin and glycoprotein lb markers as a function of heparin dose administered in vivo. At concentrations
•greater than 1 U/ml, heparin augments the ADP-and epinephrine-induced increase in platelet-surface P-selectin (SI2) ( Figure 5A ) and concomitant decrease in platelet-surface glycoprotein lb (TM60) ( Figure 5B It has been recognized for over a decade that heparin used during cardiopulmonary bypass can contribute to the development of an hemorrhagic diathesis by a number of different mechanisms. Fareed first reported an increase in t-PA levels in normal volunteers after the administration of both lam subcutaneous and intravenous heparin (9). Subsequent studies by Giul and colleagues further proved that heparin was profibrinolytic when they showed that D-dimer was increased during cardiopulmonary bypass (13).
Basic studies at the molecular and cellular level have been lacking, but a recent study showed that heparin (and heparin-like compounds) is capable of inducing an increase of 10-to 17-fold in cell-surface plasminogen activation (31).
As heparin generates a profibrinolytic state, plasmin antigen levels, as well as activity, are increased. This rise in plasma levels of plasmin may lead to cleavage of GPIb or to proteolysis of von Willebrand proteins as suggested by in vitro studies (1) . The importance of reversing the fibrinolysis that occurs with cardiopulmonary bypass and heparin administration has been underscored by studies in which bleeding tendencies were reversed or at least decreased using plasmin inhibitors such as aprotinin (6, 5) or e-aminocaproic acid (38). For example, aprotinin administration prior to bypass has been shown to prevent the formation of FDP and the consumption of a 2 -antiplasmin activity (6) . Others have demonstrated a significant decrease in blood loss, as well as a decrease in non-donor directed blood use, following the administration of aprotinin prior to cardiopulmonary bypass (5).
This in vivo effect of aprotinin has been postulated to be secondary to aprotinin's ability to inhibit the plasmin-induced cleavage of GPIb (39), although we were unable to substantiate this mechanism in earlier studies 
